ABSTRACT
Insulin-dependent diabetes mellitus (IDDM) in humans and in nonobese diabetic (NOD) mice is an immune-mediated disorder in which mononuclear cells invade the pancreatic islets of Langerhans (insulitis), resulting in the selective destruction of the insulin-secreting pancreatic 13 cells, while sparing other islet cell types (1) . Because the clinical applicability of pancreatic islet transplantation is severely limited by the scarce supply of suitable donor islet tissue, poor islet viability, and aggressive recurrence of autoimmunity in transplanted islet grafts (2) , efforts have been made to engineer non-islet cells for insulin gene delivery in IDDM.
Hepatocytes and the anterior pituitary tumor cell line, AtT20, have been studied. Proinsulin processing to insulin is extremely inefficient in hepatocytes (3, 4) , which have only a constitutive pathway of protein secretion. In contrast, AtT20 cells also have a regulated secretory pathway, with characteristic secretory granules containing the prohormone endopeptidases PC2 (5) , PC1/ PC3 (6) , and carboxypeptidase H (7) that normally convert the prohormone proopiomelanocortin (POMC) to corticotropin (ACTH) and other peptides. When transfected into AtT20 cells, proinsulin is processed to mature insulin, identical in structure to native (i.e., 1-cell derived) insulin (8, 9) . A major limitation of using transfected anterior pituitary cells for insulin gene delivery is that their major endogenous secretory product is ACrH, and thus implantation of these cells into diabetic recipients resulted in a severe Cushings-like hypercortisolemic syndrome (10) . In addition, like many transformed 13-cell lines, AtT20 cells have an active constitutive pathway, with proinsulin comprising up to 25% of the secreted immunoreactive insulin (11) .
Whereas the advantages of various candidate cell lines have been compared in terms of proinsulin processing and other characteristics, their ability to survive the autoimmune attack that destroys 13 cells has not been evaluated. In the present study, insulin expression was targeted, using transgenic mouse techniques, to POMC-expressing pituitary cells in NOD mice. We demonstrate that the transgenic intermediate lobe pituitary cells efficiently process and secrete mature insulin via a regulated secretory pathway and yet, unlike insulin-producing 13 cells, they are resistant to immune-mediated destruction. In view of these immunological and biochemical features, the feasibility of using these cells as an insulin gene delivery system in IDDM was tested. The methodology used may provide a novel means of identifying other B3-cell autoantigens targeted by the autoimmune cascade.
METHODS
Construction of the Transgene. The POMC-Ins transgene consisted of the POMC promoter region linked to the structural region of the mouse preproinsulin II (Ins) gene (see Fig. 1A ). To excise the 5' regulatory region of the Ins gene and yet preserve the translation initiation start site at position 1132, a novel HindlIl restriction site was created at position 985 by site-directed mutagenesis using the recombination polymerase chain reaction (PCR) technique (12) . A 2.4-kb genomic BamHI Ins fragment (13) was cloned into pBluescript (pBS, Stratagene). The recombinant Ins-pBS vector was linearized in two separate restriction enzyme digestion reactions with BalI (position 846) and PfiMI (position 1237). These templates were then amplified in two separate PCR reactions using primer 3, 5'-CAATCAAAAAGCT-TCAGCAAGCAGGAAGGTAC-3' (corresponding to sense nucleotides 977-1008, mutagenesis sites are underlined and the region of complementarity to primer 3 is in boldface type), and primer 2, 5'-TCG TGT AGA TAA CTA CGA TAC G-3' (corresponding to nucleotides 2050-2071 of pBS). The PfiMI template was amplified with primer 1, 5'-GCTGAAGCTTTTT-GATTGTAGCGGATCACTTAG-3' (corresponding to antisense nucleotides 994-962, mutagenesis sites are underlined and the region of complementarity to primer 1 is in boldface type), and primer 4 (the entire primer 4 was complementary to primer 2). The PCR products were mixed together and cotransfected into bacteria. The BalI/PfiMI fragment of a plasmid containing the Hindlll mutation was then ligated into Ins-pBS that had not undergone PCR amplification. DNA sequencing of the PCRamplified HindIII/PfiMI region did not reveal any cloning artifacts or polymerase errors.
By successive ligations, the HindIlI Ins structural gene and the POMC promoter [position -703 bp to position +61 bp (14) ] were subcloned into pBS. This promoter region has previously been shown to confer cell-specific expression and correct hormonal regulation in anterior and intermediate lobe cells of transgenic mice (14, 15) .
Generation of the NOD Transgenic Mice. The POMC-Ins fusion gene cassette was excised from pBS by digestion with XhoI/EcoRV (see Fig. 1A ). The cassette was purified for microinjection and was microinjected directly into the pronuclei of 1-cell embryos of NOD mice (16 15 hr in the same medium containing 10 mM L-leucine and 10% fetal bovine serum. After removal of the radiolabeled media, the cells were washed with 2.0 ml of modified Krebs-Ringer bicarbonate buffer containing 20 mM Hepes, 0.1% bovine serum albumin, and 11 mM glucose, and incubated for 30 min in 500 ,ul of the same medium at 37°C. The medium was removed and the cells were incubated for 90 min first in the same medium ("basal") and then in the same medium containing 1 mM forskolin and 1 mM 2-isobutyl-1-methylxanthine ("stimulated"). At the end of each incubation period, the medium was removed and placed at -20°C pending analysis.
Pancreatic islets (n = 100), isolated from Sprague-Dawley rats, were radiolabeled for 15 hr in methionine-free RPMI 1640 medium containing 11 mM glucose, 2 mM leucine, 10% fetal bovine sera, and 0.25 mCi [35S]methionine. After this incubation period, the medium was removed and the islets were placed in 1 ml modified Krebs-Ringer bicarbonate buffer containing 2 mM methionine, 2.8 mM glucose, 20 mM Hepes, and 0.1% BSA. After a 90-min preincubation period at 37°C, the medium was removed, replaced with 1 ml fresh medium, and further incubated for 60 min. At the end of this incubation period, this medium ("basal") was collected and placed at -20°C. The same isletswere then incubated for a further 60 min with the same medium containing 16.7 mM glucose. This medium ("stimulated") was then removed and placed at -20°C.
Pituitary and islet cell lysates and the media samples were then immunoprecipitated for (pro)insulin and analyzed by alkalineurea PAGE as previously described (18) .
RESULTS
Expression of Insulin in the Pituitaries of Transgenic NOD Mice. Northern blot analysis revealed an abundant 550 bp insulin transcript in the pituitary, identical in size to the endogenous pancreatic insulin transcript. In contrast, RNA from transgenic hypothalamus, brain, thymus, spleen, lymph nodes, testes, kidney, liver, and salivary gland did not show any detectable signals (Fig.  1B) . Immunocytochemistry of the pituitaries from the transgenic animals ( Fig. 2A) showed that a small percentage of cells in the anterior lobe (A) and the great majority of cells in the intermediate lobe (I) stained positive for insulin (Top), similar in distribution to ACTH immunostaining (Middle). The posterior pituitary (P) was devoid of specific insulin immunostaining and showed background signals similar to nontransgenic control pituitaries (Bottom). Colocalization of insulin and ACTH (or POMC) immunoreactivity to the same pituitary cells was demonstrated by double immunolabeling the same frozen section (Fig. 2B) . Of note, the ACTH antibody used in these studies was raised against the entire ACTH molecule (i.e., , E I! Northern blot analysis of a transgenic NOD mouse demonstrating pituitary-specific expression of insulin that is similar in size to the endogenous (pancreatic) transcript. Twenty micrograms of total cellular RNA was used for each of the various tissues, except for the pituitary and hypothalamus from which the amount of RNA extracted per animal was too low for spectrophotometry, and thus the entire amount of RNA isolated per animal was loaded. The relatively low insulin signal in the pancreas may reflect partial degradation of the pancreatic RNA and that the islet cell mass makes up only about 1% of the total pancreas. The Northern blot was sequentially hybridized to 32P-labeled insulin and ,B-actin probes (16) . glucose sensing apparatus including the glucose transporter GLUT-2, insulin secreted from the pituitary would not be expected to respond to ambient glucose levels (19) . Indeed, with a 60% drop in BG in control NOD mice during the fast [from 112 ± 6.0 to 46 ± 1.6 mg/dl (n = 12)], serum insulin levels fell below the detection limits of the radioimmunoassay. In contrast, despite similar drops in BG levels in heterozygous and homozygous transgenic mice (from 102 ± 7.6 to 41 ± 2.2 mg/dl and 107 ± 7.4 to 43 ± 1.0 mg/dl, respectively), serum insulin levels after the 48-hr fast were markedly elevated, averaging 43.3 ± 4.2 (n = 8) and 94.6 ± 8.6 microunit per ml (n = 8), respectively. These in vivo data demonstrate that the ectopically produced insulin was secreted into the circulation.
Proinsulin the secretagogues forskolin and 3-isobutyl-1-methylxanthine (IBMX) during subsequent chase periods were identified by immunoprecipitation followed by alkaline urea-PAGE. These studies showed that, similar to proinsulin processing in normal islets, little insulin was detectable in the media in the basal state, but secretion was greatly enhanced in response to forskolin and IBMX (Fig. 3) (20, 21) it was of interest to examine whether the expression of insulin in the pituitary, which is not normally involved by autoimmunity in NOD mice, would engender the development of ectopic lymphocytic infiltrates (i.e., hypophysitis). However, serial examination of the pituitaries from these transgenic NOD mice (and from other POMC-Ins transgenic NOD mouse lines that we generated) did not reveal the presence of ectopic lymphocytic infiltration, even after the onset of diabetes. To exclude the possibility that either the anatomical location of the pituitary gland or the sustained production of insulin in the transgenic NOD mice might be impairing immune responsiveness to the ectopically expressed insulin, we transplanted transgenic pituitaries and control islets under the kidney capsules of "naive" (nontransgenic) overtly diabetic NOD recipients. As expected, when control islet grafts were removed from the kidney capsule of the recipients 2 weeks after transplantation, the grafts showed severe infiltration with complete loss of the insulin-staining 13 cells, with only non-X3 cells remaining (Fig. 4A) . In striking contrast, the transgenic pituitary grafts, placed under the capsule of the contralateral kidney, were devoid of lymphocytic infiltration (Fig. 4B ) and showed abundant staining for insulin and ACTH. Thus, the ectopic expression of insulin in the pituitary did not elicit the development of pathologic lesions.
One possible explanation for these findings was that in the absence of antecedent cell injury or of a "triggering event" similar to that which leads to insulitis, the transgenic pituitaries might not contain sufficient numbers of antigen-presenting cells to activate the relevant lymphocytes to effect destruction of the insulinexpressing pituitary cells. To address this concern and to examine the relative ability of the intermediate lobe pituitary cells to withstand inflammatory damage, islet and transgenic pituitary cells were mixed together and engrafted into a single site under the kidney capsules of diabetic NOD mice. This resulted in the development of severe lymphocytic infiltration over the entire graft, including areas containing pituitary tissue (Fig. 4C , arrowhead). Although there was complete destruction of insulinproducing 1-cells in the islets, the insulin-positive cells of the pituitary remained intact. Indeed, the only insulin-positive cells that remained in the grafts colocalized with ACTH staining and were thus pituitary derived. These studies indicate that, even when placed in direct contact with islet-specific pathogenic lymphocytes [presumptively, many of which are insulin-specific (22) (Fig. 5A ) and in the complete remission from diabetic symptoms. This was associated with the progressive return to near normoglycemia (Fig. SB) , with mean BG levels decreasing from 484 ± 21 mg/dl pretransplantation to 150 ± 43 mg/dl after transplantation (n = 6). In parallel with this drop in BG, random insulin levels increased from 4 ± 0.2 microunits per ml pretransplantation to 42 ± 9 microunits per ml Medical Sciences: Lipes et al. posttransplantation, in a similar range to random insulin levels of nondiabetic control mice [39 ± 9 microunits per ml (n = 6)]. At the end of the transplantation period, immunohistochemistry of the grafts of the recipients showed abundant insulin staining with no evidence of lymphocytic infiltration. As expected, the pan- creatic islets of these animals were severely atrophied and devoid of insulin-positive cells, confirming that the enhanced insulin levels posttransplantation were due to the transgenic tissue implants (data not shown). These results demonstrate that the intermediate pituitary-derived insulin is biologically active and are consistent with our biochemical studies which showed that the great majority of insulin secreted by the transgenic pituitaries is fully processed, mature insulin. to tissue specific differences in prohormone processing, ACTH is (28) and/or susceptibility to destruction. In addition, if the primary autoantigen(s) is to be recognized in the context of MHC antigens, there may be tissue-specific differences in the nature and amount of antigenic peptides processed and presented by these non-islet tissues to cells of the immune system. Regardless of the exact mechanism(s) underlying the ability of the insulin-producing intermediate lobe pituitaries to elude immune system recognition and attack, this feature is clearly advantageous for transplantation purposes. A limitation of this current gene delivery system is that insulin secretion in the intermediate lobe pituitary cells was not glucose regulated. It has recently been shown, however, that transfection of AtT20 pituitary cells with the (-cell glucose transporter GLUT-2 could confer glucose-stimulated insulin synthesis and secretion (19) . Thus, while further molecular manipulations will be probably be necessary for these non-islet cell types to be useful as gene replacement therapy in IDDM, these studies demonstrate in vivo the potential of this approach.
